G. Jerusalem Et Al. , "Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial," EUROPEAN JOURNAL OF CANCER , vol.49, 2013
Jerusalem, G. Et Al. 2013. Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial. EUROPEAN JOURNAL OF CANCER , vol.49 .
Jerusalem, G., Andre, F., Chen, D., Robinson, D., Ozguroglu, M., Lang, I., ... White, M.(2013). Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial. EUROPEAN JOURNAL OF CANCER , vol.49.
Jerusalem, G. Et Al. "Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial," EUROPEAN JOURNAL OF CANCER , vol.49, 2013
Jerusalem, G. Et Al. "Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial." EUROPEAN JOURNAL OF CANCER , vol.49, 2013
Jerusalem, G. Et Al. (2013) . "Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial." EUROPEAN JOURNAL OF CANCER , vol.49.
@article{article, author={G. Jerusalem Et Al. }, title={Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial}, journal={EUROPEAN JOURNAL OF CANCER}, year=2013}